Morning Market Gainers

shares jumped 47.57 percent to $5.77 after the company reported positive top-line results from METEOR, Phase 3 pivotal trial of Cabozantinib vs. Everolimus in patients with metastatic renal cell carcinoma.

shares climbed 43.89 percent to $15.67 after the company agreed to be acquired by

for $2.2 billion.

shares surged 9.50 percent to $117.81 on better-than-expected Q2 earnings.

gained 5.66 percent to $82.68 after the company reported upbeat Q2 results.

rose 5.23 percent to $39.02 after the company issued a strong Q2 sales forecast.

shares surged 3.19 percent to $41.28 after the company reported stronger-than-expected results for its second quarter.

shares gained 3.07 percent to $41.00. Bank of America initiated coverage on Cellectis with a Buy rating and a $50.00 price target.

shares rose 1.65 percent to $40.90 after the company reported upbeat earnings for the second quarter.